Melanoma Coverage From Every Angle
Advertisement
Advertisement

Could the Protein Leucurogin Hinder the Growth of Melanoma Cells?

By: Kayci Reyer
Posted: Monday, January 21, 2019

According to preclinical research published in Toxicon, the protein leucurogin was found to inhibit tumor growth by more than 40% in human melanoma cells grafted into the skin of mice. Created through recombinant technology, leucurogin, which is cloned from the venom of a white-tailed snake, seems to warrant further study as a potential treatment of melanoma.

Ivan C. Santos, PhD, of the Federal University of São João del-Rei, Brazil, and colleagues assessed the biologic and functional characteristics of leucurogin both in vivo and in vitro. The protein was found to hinder cellular processes that rely on collagen I and to inhibit the adherence of human fibroblasts to collagen, dependent on the dose used.

At 2.5 μM, leucurogin reduced the proliferation of B16F10 Nex-2 melanoma cells by 80%. A dose of 10 μM reduced human fibroblast adhesion to collagen by 40% and its migration by 70%; this dose also prevented the migration (32%) and proliferation (65%) of BLM (human melanoma) cells. In vitro, a treatment of 4.8 μM of leucurogin reduced the formation of vascular structures by endothelial cells by 66%. When injected intraperitoneally into 2-month-old C57/B16 male mice at 5 μg per animal every other day for 15 days, the protein hindered lung metastasis of B16F10 Nex-2 cells by 70% to 75%. To achieve the 40% prevention of tumor growth in human melanoma grafted into the skin of mice, a dose of 7.5 μg/kg of leucurogin was administered every other day for 17 days.

“This work highlights that leucurogin can open a new approach to downstream tumor-cell signaling studies that could also include an intracellular regulation model,” the researchers concluded. “We also encourage the study of leucurogin-integrin interaction to unveil its functional molecular structure.”

Disclosure: The study authors reported no conflicts of interest.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.